DEEP Platform Showcases

Discover concise spotlights on high‑value digital measures - curated for teams needing fast, credible insight. Each article distills structured evidence from the DEEP Platform into clear takeaways you can use to assess relevance, maturity, and regulatory readiness. Perfect for teams evaluating new endpoints, shaping strategy, or exploring what 'good' looks like in digital measurement.
Calling for Collaborators - View latest engagement opportunities here!

March 2026 | Pfizer-Led, Multi Stakeholder Initiative To Harmonize Physical Activity Measurement Definitions: Join our Pfizer-led consortium, to establish cross-industry consensus on terminology and definitions for measures of physical activity.

Contact us to find out more | Read more about this opportunity

January 2026 | Navigating Health Technology Assessment (HTA) ​Expectations for Digital Measure Approval: Join our mission and take positive steps towards successful HTA interactions.

Contact us to find out more | Read more about this opportunity

General Showcase Items
  • There are no suggestions because the search field is empty.

Digital Measures for Respiratory Conditions: A Pre-competitive Mission for COPD and Non-CF Bronchiectasis

This DEEP Measures-led precompetitive mission seeks to align industry stakeholders on regulatory-ready digital measures for respiratory conditions, beginning with COPD and non-CF bronchiectasis,...

A Pfizer-Led, Multi-Stakeholder Initiative To Harmonize Physical Activity Measurement Definitions

This Pfizer-led consortium, in partnership with DEEP Measures, seeks to establish cross-industry consensus on terminology and definitions for measures of physical activity, creating a shared...

Unifying Digital Measures in Parkinson's Disease

Building Digital Measures for PD? DEEP can help! Clinical trials in PD have relied on snapshot, clinic-based assessments for too long. We're changing that: bringing pharma, biotech, researchers,...

Call for Collaborators to Define New Digital Measures in Myasthenia Gravis

Developing precise and comprehensive digital measures for Myasthenia Gravis (MG) that capture meaningful aspects of the disease and address unmet needs in patient care and drug development.

Digital Measure Collaboration: Sleepiz One+ for OSA Endpoints in Metabolic Clinical Trials

Following the precedent set by successful GLP-1 trials in Obstructive Sleep Apnea (OSA), expansion of drug labels into this highly prevalent and impactful condition is the new frontier for metabolic...

The DEEP Nice Advice pilot mission: The way medicines reach European patients has changed - the time to prepare is now!

Why this matters now ? Authorities increasingly want exactly what digital measures are built to deliver: continuous, patient-relevant outcomes from wearables, sensors and apps. At the same time, the...